Cantargia (OMX: CANT)

Currency in SEK

Last close As at 25/01/2023

SEK6.58

−0.82 (−11.08%)

Market capitalisation

SEK1,164m

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.

Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net cash (SEKm)

217.6

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 108.2 73.4 (47.7)
Relative 93.1 53.6 (43.5)
52 week high/low SEK16.5/SEK3.0

Financials

Cantargia is developing antibodies against IL1RAP. Data from its Phase IIa CANFOUR trial, investigating nadunolimab in first-line non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy. At the ASCO Annual Meeting in June, Cantargia presented promising interim results for nadunolimab from a Phase I/IIa in PDAC and a Phase IIa trial in NSCLC.

The company is now preparing for the Phase II/III trial in metastatic PDAC in collaboration with PanCAN. A second programme, CAN10, is being developed for treatment of myocarditis and systemic sclerosis. New supportive preclinical data were recently presented and Phase I clinical trials are planned for early 2023. Nadunolimab is being investigated across eight different cancers in different combinations. Cantargia had a cash and short-term investment position of SEK496.5m at end-Q322.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2020A 0.0 (170.7) (173.1) (193.65) N/A N/A
2021A 0.0 (366.8) (366.5) (365.80) N/A N/A
2022E 0.0 (330.8) (322.8) (240.98) N/A N/A
2023E 0.0 (294.0) (296.7) (177.15) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free